AC Immune Stock
AC Immune S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Martin Zügel
- Employees
- 106
- Market cap
- $243 M
- IPO
- 23/09/2016
AC Immune S.A. is a clinical stage biotechnology company headquartered in Lausanne, Switzerland. The firm focuses on pioneering, formulating, and advancing therapeutic agents and diagnostic tools to address neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
AC Immune stock: price history
1D
-2.4%
1W
-4.4%
1M
-9.8%
6M
-20.6%
YTD
-23.9%
1Y
-19.3%
2Y
-25.1%
5Y
-61.3%
10Y
-84.3%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~5% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about AC Immune
Analyst assessment of AC Immune
PRICE TARGET LOW
US$7.00
CONSENSUS
US$8.33
MEDIAN
US$8.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 23/09/2026
AC Immune stock metrics
P/E
-4.57
P/B
5.53
EV/EBITDA
-4.24
RETURN ON EQUITY
5.3%
NET MARGIN
12.4%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
61.5%
FLOAT SHARES
62,561,292
AVG. DAILY VOLUME (30D)
184,079
Insider transactions (SEC)
June Carl Howard
Buetler Monika
Zuegel Martin
AGUIAR-LUCANDER RENEE
Twyman Roy Ervin
Institutional holders
Comparable stocks
Frequently asked questions about AC Immune stock
What does AC Immune do?
AC Immune S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Martin Zügel, the company employs around 106 people.
The IPO was on 23/09/2016; the stock trades on NASDAQ under the ticker ACIU.
What do analysts say about AC Immune stock?
9 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$8.33, ranging from US$7.00 to US$10.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does AC Immune report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does AC Immune pay a dividend?
No, AC Immune currently does not pay a dividend.
Which stocks are comparable to AC Immune?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get AC Immune stock analyzed?
Clicking "Analyze stock" lets five strategies assess AC Immune against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.